Hiroaki Ohmori

Whole-body energy mapping under physical exercise using positron emission tomography.

We attempted to visualize dynamic adjustment of glucose utilization in humans in the whole-body organs during physical exercise by using three-dimensional positron emission tomography (3D-PET) and [18F]-2-fluoro-deoxy-glucose (FDG). Twelve healthy male volunteers collaborated on the study; six subjects were assigned to the resting control group (C) and the other six to the running group (E). Group E subjects performed running on a flat road for 35 min. After 15 min of running, subjects injected FDG and kept on running thereafter for another 20 min. Group C subjects sat on a comfortable chair in a quiet room for 35 min after the injection of FDG. After scanning by PET, the regions of interest (ROIs) were manually set on brain, heart, thorax, abdomen, lower extremities, and the rest of the body on the corresponding transaxial images. The uptake of FDG in each region was evaluated as the % fraction of FDG accumulation relative to the total amount of whole-body accumulation. The results revealed increase of FDG uptake after running in the lower leg muscles from 24.6 +/- 9.5% to 43.1 +/- 4.7% and in the heart from 2.3 +/- 0.4% to 2.8 +/- 0.6%. The differences were significant (P < 0.05). These increases reflect the rise in energy consumption in leg and heart muscles and were balanced by the reduction of energy consumption in the other part of the body. FDG uptake in the abdominal region reduced from 37.3 +/- 7.2% to 19.7 +/- 4.9%. However, FDG uptake in the brain remained stable, i.e., 11.9 +/- 2.8% at rest and 10.3 +/- 2.5% after exercise. Thus, 3D-PET is a tool to visualize the dynamic adjustment of energy consumption during physical exercise in humans.

Comparative genomic hybridization and mutation analyses of sporadic schwannomas

SummarySchwannomas of the vestibular nerve are the striking characteristics of neurofibromatosis type 2 (NF2), an autosomal dominant hereditary disease. The NF2 gene on 22q12 has been isolated as the gene responsible for NF2. Previous studies have reported that 60% of sporadic schwannomas showed inactivation of the NF2 gene, but genetic alterations of remaining 40% tumors remain elusive. Moreover, detailed genetic alterations of this tumor remain an open question. In this study, we analyzed genomic alterations in 17 sporadic schwannomas using comparative genomic hybridization (CGH). Loss of chromosome 22q, including the NF2 locus, was the only notable abnormality (5/17, 29%). Further, we performed fluorescence insitu hybridization analysis with a genomic BAC clone harboring the NF2 gene and found that the 5 tumors with loss detected by CGH as well as three cases without such a detectable loss by CGH, or a total, 8/17 (47%), showed loss of the NF2 locus. Mutation search by PCR-SSCP followed by direct sequencing revealed that 71% (12/17) of the tumors had one or two mutations in the NF2 gene. Our analyses disclosed that 14 (82%) of 17 tumors had structural alteration of NF2; among these 14 cases, 9 (64%) had two inactivating mutations in the NF2 gene, either a somatic mutation in one allele coupled with loss of the other allele or two independent somatic mutations. Our present results suggested that (i) most of the sporadic schwannomas have two-hit mutations in the NF2 gene, and (ii) NF2 is the only major causative gene in the genesis of schwannomas that is activated or inactivated by copy number alterations.